Orai2 Inhibitors

The chemical class of Orai2 inhibitors comprises a range of compounds that modulate the activity of the Orai2 protein, a component of the calcium release-activated calcium (CRAC) channel complex, which plays a crucial role in calcium signaling in various cells. These inhibitors work by affecting different aspects of the calcium signaling pathway and the functioning of Orai2. The first paragraph highlights the mechanisms through which these inhibitors impact Orai2 activity. Compounds like 2-Aminoethoxydiphenyl borate (2-APB) and SKF-96365 function by interfering with store-operated calcium entry, a crucial pathway involving Orai2. These inhibitors alter the gating properties of the calcium channels or inhibit the pathway entirely, leading to reduced calcium influx through Orai2. Similarly, ions like La3+ and Gd3+ act by competitively inhibiting calcium ions at the channel sites, directly blocking the channel pore of Orai2 and thus inhibiting calcium influx.

The second paragraph delves into how other inhibitors in this class affect Orai2 indirectly. Inhibitors like ML-9 and U-73122 target upstream kinases and phospholipase C (PLC), respectively, which are involved in the activation and regulation of Orai2. By modulating these upstream molecules, these inhibitors can decrease the activation and function of Orai2 channels. Additionally, compounds such as YM-58483 (BTP2), Synta66, and Econazole selectively target store-operated calcium entry pathways and interact with membrane components to modulate the activity of Orai2 channels. Furthermore, calcium channel blockers like Nitrendipine, Verapamil, and Nifedipine, although primarily known for their effects on cardiac tissue, can also influence Orai2 by altering calcium influx in various cell types.